Organogenesis (Nasdaq: ORGO) applauded CMS’s finalization of payment reform for skin substitutes/CTPs under the CY 2026 Physician Fee Schedule announced Nov. 3, 2025.
The company highlighted that CMS finalized FDA classifications and a per centimeter-square payment methodology for both physician office and hospital outpatient settings, and said CMS recognized the clinical differentiation of PMA products, which the company believes will increase access and support higher payment and expanded access for PMA technologies. Organogenesis reiterated its multi-decade leadership and said its evidence-based portfolio positions it well for the skin substitutes market in 2026 and beyond.
The release contains forward-looking statements and cautions that actual outcomes are subject to risks and uncertainties described in the company’s SEC filings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.